Moderna signals diversity of its US COVID-19 vaccine trial cohort
Moderna has flagged the diversity of the US-based Phase 3 trial of its COVID-19 vaccine candidate, mRNA-1273, for which enrollment, now at 30,000, has completed.
Archives for October 23, 2020